References
- 1. Zorlu A, Tandogan I, Yilmaz MB, et al. Burden of Systolic and Diastolic Ventricular. J Am Coll Cardiol. 2015;18(3):1-7. doi: 10.1159/00036060910.1159/000360609
- 2. McMurray JJ V, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart. Rev Port Cardiol. 2013;32(7-8):e1--641--e61. doi:10.1093/eurheartj/ehs10410.1093/eurheartj/ehs104
- 3. Turgut O, Tandogan I, Yilmaz MB, Gul I, Zorlu A. CA125 in heart failure: Implications for immunoinflammatory activity. Int J Cardiol. 2011;146(1):99-100. doi:10.1016/j.ijcard.2010.05.07710.1016/j.ijcard.2010.05.077
- 4. Huang F, Zhang K, Chen J, et al. Elevation of carbohydrate antigen 125 in chronic heart failure may be caused by mechanical extension of mesothelial cells from serous cavity effusion. Clin Biochem. 2013;46(16-17):1694-1700. doi:10.1016/j.clinbiochem.2013.09.00810.1016/j.clinbiochem.2013.09.008
- 5. Monteiro S, Franco F, Costa S, et al. Prognostic value of CA125 in advanced heart failure patients. Int J Cardiol. 2010;140(1):115-118. doi:10.1016/j.ijcard.2008.11.02310.1016/j.ijcard.2008.11.023
- 6. Zorlu A, Tandogan I, Yilmaz MB. CA-125, an omitted part of the heart. Hear Lung Circ. 2011;20(5):345. doi:10.1016/j.hlc.2011.01.02510.1016/j.hlc.2011.01.025
- 7. Yilmaz MB, Nikolaou M, Solal AC. Tumour biomarkers in heart failure: Is there a role for CA-125? Eur J Heart Fail. 2011;13(6):579-583. doi:10.1093/eurjhf/hfr02210.1093/eurjhf/hfr022
- 8. Topatan B, Basaran A. CA-125 and heart failure: Deja vu or “still to be seen.” Int J Cardiol. 2010;145(3):626-629. doi:10.1016/j.ijcard.2010.09.060
- 9. Napan S, Aussawapokee T, Nargileci E, Qureshi A, Khadra S, Stroger JH. Prognostic Significance of Carbohydrate Antigen 125 in Patients With Heart Failure and Preserved Ejection Fraction. J Am Coll Cardiol. 2010;55(10):A30.E292. doi:10.1016/S0735-1097(10)60293-8
- 10. Nunez J, Minana G, Nunez E, Sanchis J. Antigen carbohydrate 125 in heart failure: A promising clinical tool. Int J Cardiol. 2011;150(3):369-370. doi:10.1016/j.ijcard.2011.05.089
- 11. Sánchez-Marteles M, Rubio Gracia J, Giménez López I. Pathophysiology of acute heart failure: a world to know. Rev Clin Esp. 2015;216(1):38-46. doi:10.1016/j.rce.2015.09.01010.1016/j.rce.2015.09.010
- 12. Kälsch H, Neumann T, Erbel R. Less increase of BNP and NT-proBNP levels in obese patient with decompensated heart failure. Interpretation of natriuretic peptides in obesity. Int J Cardiol. 2009;133(1):e22-e24. doi:10.1016/j.ijcard.2007.08.09810.1016/j.ijcard.2007.08.098
- 13. Madamanchi C, Alhosaini H, Sumida A, Runge MS. Obesity and natriuretic peptides, BNP and NT-proBNP: Mechanisms and diagnostic implications for heart failure. Int J Cardiol. 2014;176(3):611-617. doi:10.1016/j.ijcard.2014.08.00710.1016/j.ijcard.2014.08.007
- 14. Gentili A, Frangione MR, Albini E, et al. Modulation of natriuretic peptide receptors in human adipose tissue: molecular mechanisms behind the “natriuretic handicap” in morbidly obese patients. Transl Res. 2017;186:52-61. doi:10.1016/j.trsl.2017.06.00110.1016/j.trsl.2017.06.001
- 15. Kinoshita K, Kawai M, Minai K, Ogawa K, Inoue Y, Yoshimura M. Potent influence of obesity on suppression of plasma B-type natriuretic peptide levels in patients with acute heart failure: An approach using covariance structure analysis. Int J Cardiol. 2016;215:283-290. doi:10.1016/j.ijcard.2016.04.11110.1016/j.ijcard.2016.04.111
- 16. Ricci MA, De Vuono S, Pucci G, et al. Determinants of low levels of brain natriuretic peptide in morbid obesity. Clin Nutr. 2017;36(4):1075-1081. doi:10.1016/j.clnu.2016.06.02410.1016/j.clnu.2016.06.024